Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078389 · ClinicalTrials.gov registry record · Phase 2
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
NCT01078389 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 314 participants.
The verdict
NCT01078389, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
Study Summary
This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
Interventions
- DRUG Febuxostat
- DRUG Placebo for Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078389
The ClinicalTrials.gov registry entry for NCT01078389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Febuxostat is the first listed.
NCT01078389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078389 about?
NCT01078389 is a clinical study titled "Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout". This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.
What is the current status of trial NCT01078389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2010-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01078389?
The interventions under investigation include: Febuxostat (DRUG), Placebo for Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01078389?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.